Kane Biotech Inc. (KNE.V)
CAD 0.1
(0.0%)
CAD 0.1
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.03 Million CAD | -29.41% |
| 2022 | -3.88 Million CAD | 15.52% |
| 2021 | -4.6 Million CAD | -23.89% |
| 2020 | -3.71 Million CAD | -287.08% |
| 2019 | -960.17 Thousand CAD | 70.56% |
| 2018 | -3.26 Million CAD | -17.04% |
| 2017 | -2.78 Million CAD | -9.32% |
| 2016 | -2.54 Million CAD | -49.05% |
| 2015 | -1.7 Million CAD | -5.89% |
| 2014 | -1.61 Million CAD | -11.58% |
| 2013 | -1.44 Million CAD | 0.83% |
| 2012 | -1.45 Million CAD | -19.52% |
| 2011 | -1.22 Million CAD | -25.47% |
| 2010 | -973.25 Thousand CAD | -10.94% |
| 2009 | -877.24 Thousand CAD | 18.54% |
| 2008 | -1.07 Million CAD | 1.2% |
| 2007 | -1.08 Million CAD | -14.04% |
| 2006 | -955.75 Thousand CAD | 5.34% |
| 2005 | -1 Million CAD | -67.56% |
| 2004 | -602.56 Thousand CAD | -48.58% |
| 2003 | -405.54 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.39 Million CAD | 11.77% |
| 2024 Q2 | 9.18 Million CAD | 757.86% |
| 2023 FY | -5.03 Million CAD | -29.41% |
| 2023 Q1 | -1.2 Million CAD | -38.08% |
| 2023 Q2 | -967.9 Thousand CAD | 19.42% |
| 2023 Q4 | -1.58 Million CAD | -14.78% |
| 2023 Q3 | -1.37 Million CAD | -42.41% |
| 2022 Q3 | -1.01 Million CAD | -12.38% |
| 2022 Q4 | -869.88 Thousand CAD | 13.99% |
| 2022 Q2 | -899.99 Thousand CAD | 18.82% |
| 2022 Q1 | -1.1 Million CAD | 12.63% |
| 2022 FY | -3.88 Million CAD | 15.52% |
| 2021 Q1 | -908.46 Thousand CAD | -11.26% |
| 2021 Q3 | -1.52 Million CAD | -68.36% |
| 2021 Q4 | -1.26 Million CAD | 16.68% |
| 2021 Q2 | -904.48 Thousand CAD | 0.44% |
| 2021 FY | -4.6 Million CAD | -23.89% |
| 2020 Q2 | -505.39 Thousand CAD | 62.94% |
| 2020 Q4 | -816.5 Thousand CAD | 20.8% |
| 2020 Q3 | -1.03 Million CAD | -103.99% |
| 2020 Q1 | -1.36 Million CAD | -17.91% |
| 2020 FY | -3.71 Million CAD | -287.08% |
| 2019 Q2 | 1.67 Million CAD | 354.86% |
| 2019 Q3 | -821.55 Thousand CAD | -149.03% |
| 2019 Q4 | -1.15 Million CAD | -40.79% |
| 2019 FY | -960.17 Thousand CAD | 70.56% |
| 2019 Q1 | -657.39 Thousand CAD | 2.29% |
| 2018 Q4 | -672.8 Thousand CAD | 32.5% |
| 2018 Q1 | -889.79 Thousand CAD | -0.13% |
| 2018 Q2 | -701.71 Thousand CAD | 21.14% |
| 2018 FY | -3.26 Million CAD | -17.04% |
| 2018 Q3 | -996.68 Thousand CAD | -42.04% |
| 2017 Q4 | -888.68 Thousand CAD | -2.24% |
| 2017 FY | -2.78 Million CAD | -9.32% |
| 2017 Q3 | -869.24 Thousand CAD | -9.95% |
| 2017 Q1 | -237.69 Thousand CAD | 52.47% |
| 2017 Q2 | -790.54 Thousand CAD | -232.59% |
| 2016 FY | -2.54 Million CAD | -49.05% |
| 2016 Q4 | -500.05 Thousand CAD | 18.83% |
| 2016 Q2 | -851.27 Thousand CAD | -46.43% |
| 2016 Q3 | -616.06 Thousand CAD | 27.63% |
| 2016 Q1 | -581.35 Thousand CAD | -21.59% |
| 2015 Q2 | -332.89 Thousand CAD | 31.66% |
| 2015 Q4 | -478.14 Thousand CAD | -16.1% |
| 2015 FY | -1.7 Million CAD | -5.89% |
| 2015 Q3 | -411.82 Thousand CAD | -23.71% |
| 2015 Q1 | -487.12 Thousand CAD | -6.99% |
| 2014 Q4 | -455.31 Thousand CAD | -33.13% |
| 2014 Q1 | -306.36 Thousand CAD | -142.88% |
| 2014 Q3 | -341.99 Thousand CAD | 33.11% |
| 2014 Q2 | -511.24 Thousand CAD | -66.88% |
| 2014 FY | -1.61 Million CAD | -11.58% |
| 2013 Q3 | -330.77 Thousand CAD | -1.47% |
| 2013 Q1 | -664.48 Thousand CAD | -59.57% |
| 2013 FY | -1.44 Million CAD | 0.83% |
| 2013 Q4 | -126.13 Thousand CAD | 61.87% |
| 2013 Q2 | -325.97 Thousand CAD | 50.94% |
| 2012 Q1 | -304.19 Thousand CAD | -1.76% |
| 2012 Q3 | -390.74 Thousand CAD | -12.24% |
| 2012 Q4 | -416.42 Thousand CAD | -6.57% |
| 2012 FY | -1.45 Million CAD | -19.52% |
| 2012 Q2 | -348.13 Thousand CAD | -14.44% |
| 2011 Q1 | -356.48 Thousand CAD | -81.02% |
| 2011 FY | -1.22 Million CAD | -25.47% |
| 2011 Q3 | -341.41 Thousand CAD | -52.2% |
| 2011 Q2 | -224.32 Thousand CAD | 37.07% |
| 2011 Q4 | -298.93 Thousand CAD | 12.44% |
| 2010 Q2 | -236.26 Thousand CAD | 14.72% |
| 2010 Q1 | -277.03 Thousand CAD | -161.98% |
| 2010 Q4 | -196.93 Thousand CAD | 25.12% |
| 2010 Q3 | -263.01 Thousand CAD | -11.32% |
| 2010 FY | -973.25 Thousand CAD | -10.94% |
| 2009 FY | -877.24 Thousand CAD | 18.54% |
| 2009 Q1 | -203.63 Thousand CAD | -51.34% |
| 2009 Q4 | -105.75 Thousand CAD | 65.62% |
| 2009 Q2 | -260.23 Thousand CAD | -27.79% |
| 2009 Q3 | -307.62 Thousand CAD | -18.21% |
| 2008 Q1 | -217.12 Thousand CAD | 25.56% |
| 2008 FY | -1.07 Million CAD | 1.2% |
| 2008 Q4 | -134.55 Thousand CAD | 63.93% |
| 2008 Q3 | -372.99 Thousand CAD | -5.91% |
| 2008 Q2 | -352.17 Thousand CAD | -62.2% |
| 2007 Q1 | -194.44 Thousand CAD | 45.05% |
| 2007 Q2 | -382.3 Thousand CAD | -96.61% |
| 2007 FY | -1.08 Million CAD | -14.04% |
| 2007 Q3 | -220.55 Thousand CAD | 42.31% |
| 2007 Q4 | -291.69 Thousand CAD | -32.26% |
| 2006 Q2 | -242.91 Thousand CAD | -54.69% |
| 2006 FY | -955.75 Thousand CAD | 5.34% |
| 2006 Q1 | -157.03 Thousand CAD | 43.92% |
| 2006 Q4 | -353.87 Thousand CAD | -75.25% |
| 2006 Q3 | -201.93 Thousand CAD | 16.87% |
| 2005 Q4 | -280.03 Thousand CAD | -9.58% |
| 2005 Q1 | -209.95 Thousand CAD | 15.31% |
| 2005 Q2 | -264.11 Thousand CAD | -25.8% |
| 2005 Q3 | -255.54 Thousand CAD | 3.24% |
| 2005 FY | -1 Million CAD | -67.56% |
| 2004 Q4 | -247.9 Thousand CAD | -149.99% |
| 2004 Q3 | -99.16 Thousand CAD | 33.2% |
| 2004 Q2 | -148.46 Thousand CAD | -38.7% |
| 2004 FY | -602.56 Thousand CAD | -48.58% |
| 2004 Q1 | -107.03 Thousand CAD | -111.74% |
| 2003 Q2 | -24.23 Thousand CAD | 0.0% |
| 2003 Q3 | -174.86 Thousand CAD | -621.41% |
| 2003 FY | -405.54 Thousand CAD | 0.0% |
| 2003 Q4 | -50.54 Thousand CAD | 71.09% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.32 Million CAD | -51.323% |
| Covalon Technologies Ltd. | -4.46 Million CAD | -12.847% |
| Hemostemix Inc. | -2.5 Million CAD | -101.194% |
| Universal Ibogaine Inc. | -10.49 Million CAD | 52.039% |
| MedMira Inc. | -2.67 Million CAD | -88.144% |
| Marvel Biosciences Corp. | -2.29 Million CAD | -119.697% |
| NervGen Pharma Corp. | -22.38 Million CAD | 77.508% |
| XORTX Therapeutics Inc. | -2.85 Million CAD | -76.056% |